Literature DB >> 9846702

Activation-induced apoptosis of mature T cells is dependent upon the level of surface TCR but not on the presence of the CD3 zeta ITAM.

J She1, K Matsui, C Terhorst, S T Ju.   

Abstract

Activation-induced cell death (AICD) occurs primarily in recently activated T cells after a second TCR triggering. Since a threshold in the activation status may be critical for AICD, it is likely that the CD3 ITAM, docking sites for tyrosine kinases, regulate AICD. A 'threshold model' for AICD was tested by using two targeted mutant mouse strains lacking either the zeta chain (CD3zeta-/-) or the ITAM of the zeta chain (CD3zeta-/-:Tgzetadelta67-150). Although the T cells from the CD3zeta-/- mice express extremely low levels of surface TCR, a subpopulation (approximately 18%) of activated T cells could be induced to express TCR/FcepsilonRI gamma by using a powerful polyclonal activation protocol. These activated TCR/FcRI gamma T cells were capable of undergoing AICD, but its induction required 10 times as much anti-CD3epsilon mAb as that required for AICD of wild-type T cells. Thus, the intensity of AICD correlated with the level of CD3 expression and was less efficient with activated, CD3zeta(-/-)-derived T cells. By contrast, AICD of T cells from the CD3zeta-/-:Tgzetadelta67-150 mice could be induced with low doses of anti-CD3epsilon mAb and the extent of AICD was comparable to T cells from wild-type mice. The AICD induced in T cells from CD3-/-, CD3zeta-/-:Tgzetadelta67-150 and normal controls was specifically inhibited by Fas-Ig fusion proteins. Our data support the 'threshold model' of AICD by demonstrating that AICD is controlled by the strength of T cell activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846702     DOI: 10.1093/intimm/10.11.1733

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.

Authors:  Serina Ortiz; Wenhui Lee; David Smith; Stephen J Forman; Terry D Lee; Chih-Pin Liu
Journal:  Exp Biol Med (Maywood)       Date:  2010-12

2.  Impaired activation-induced cell death promotes spontaneous arthritis in antigen (cartilage proteoglycan)-specific T cell receptor-transgenic mice.

Authors:  Ferenc Boldizsar; Katalin Kis-Toth; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant
Journal:  Arthritis Rheum       Date:  2010-10

3.  T cell receptor (TCR) signal strength controls arthritis severity in proteoglycan-specific TCR transgenic mice.

Authors:  K Olasz; F Boldizsar; K Kis-Toth; O Tarjanyi; A Hegyi; W van Eden; T A Rauch; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 4.  The power and the promise of restimulation-induced cell death in human immune diseases.

Authors:  Andrew L Snow; Pushpa Pandiyan; Lixin Zheng; Scott M Krummey; Michael J Lenardo
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

Review 5.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

6.  Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1.

Authors:  Elisa Ruffo; Valeria Malacarne; Sasha E Larsen; Rupali Das; Laura Patrussi; Christoph Wülfing; Christoph Biskup; Senta M Kapnick; Katherine Verbist; Paige Tedrick; Pamela L Schwartzberg; Cosima T Baldari; Ignacio Rubio; Kim E Nichols; Andrew L Snow; Gianluca Baldanzi; Andrea Graziani
Journal:  Sci Transl Med       Date:  2016-01-13       Impact factor: 17.956

7.  FOXP3 protects conventional human T cells from premature restimulation-induced cell death.

Authors:  Kelsey Voss; Camille Lake; Christopher R Luthers; Nathaniel M Lott; Batsukh Dorjbal; Swadhinya Arjunaraja; Bradly M Bauman; Anthony R Soltis; Gauthaman Sukumar; Clifton L Dalgard; Andrew L Snow
Journal:  Cell Mol Immunol       Date:  2019-10-28       Impact factor: 11.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.